• Immunovant Inc IMVT.OQ reported a quarterly adjusted loss of 76 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -36 cents. The mean expectation of twelve analysts for the quarter was for a loss of 75 cents per share. Wall Street expected results to range from -83 cents to -53 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Immunovant Inc's reported EPS for the quarter was a loss of 76 cents​.

• The company reported a quarterly loss of $111.12 million.

• Immunovant Inc shares had fallen by 17.6% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 1.4% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Immunovant Inc is $51.00

This summary was machine generated from LSEG data February 10 at 02:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)